Cargando…

Clinical features of Japanese patients with acute hepatic porphyria

Acute hepatic porphyria (AHP) is a family of rare genetic diseases of heme biosynthesis characterized by severe neurovisceral attacks. The clinical characteristics of patients with AHP as well as the prevalence of AHP in Japan are not well understood. The objectives of this study were to describe cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Horie, Yutaka, Yasuoka, Yuka, Adachi, Tomohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830008/
https://www.ncbi.nlm.nih.gov/pubmed/36636592
http://dx.doi.org/10.1002/jmd2.12336
_version_ 1784867575918755840
author Horie, Yutaka
Yasuoka, Yuka
Adachi, Tomohide
author_facet Horie, Yutaka
Yasuoka, Yuka
Adachi, Tomohide
author_sort Horie, Yutaka
collection PubMed
description Acute hepatic porphyria (AHP) is a family of rare genetic diseases of heme biosynthesis characterized by severe neurovisceral attacks. The clinical characteristics of patients with AHP as well as the prevalence of AHP in Japan are not well understood. The objectives of this study were to describe clinical characteristics of AHP at time of diagnosis in Japanese patients and to estimate the prevalence of AHP. Patients with porphyria were selected from Japan's Medical Data Vision health care claims database between April 2008 and June 2020. Patient characteristics before and at time of AHP diagnosis were evaluated. Prevalence per 100 000 was estimated during the study period. A total of 391 cases of AHP were included. At time of AHP diagnosis, mean age was 44 years, and the most common type was acute intermittent porphyria. Median time to diagnosis was 3 months, but some patients remained undiagnosed for several years. The most common complications included metabolic disorders (54%) and diabetes mellitus (39%). In addition, the well‐known complications of AHP, including hypertension (22%) and malignant neoplasms of digestive organs (22%), were observed. About 10% of patients received medications that may have aggravated porphyria attacks. The estimated prevalence of AHP in Japan during the study period was 1.18 cases per 100 000 population. At time of diagnosis, many patients with AHP in Japan are already experiencing a high burden of disease‐related complications. Raising AHP awareness may aid physicians in providing an earlier diagnosis and reducing lifetime disease burden.
format Online
Article
Text
id pubmed-9830008
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-98300082023-01-11 Clinical features of Japanese patients with acute hepatic porphyria Horie, Yutaka Yasuoka, Yuka Adachi, Tomohide JIMD Rep Research Reports Acute hepatic porphyria (AHP) is a family of rare genetic diseases of heme biosynthesis characterized by severe neurovisceral attacks. The clinical characteristics of patients with AHP as well as the prevalence of AHP in Japan are not well understood. The objectives of this study were to describe clinical characteristics of AHP at time of diagnosis in Japanese patients and to estimate the prevalence of AHP. Patients with porphyria were selected from Japan's Medical Data Vision health care claims database between April 2008 and June 2020. Patient characteristics before and at time of AHP diagnosis were evaluated. Prevalence per 100 000 was estimated during the study period. A total of 391 cases of AHP were included. At time of AHP diagnosis, mean age was 44 years, and the most common type was acute intermittent porphyria. Median time to diagnosis was 3 months, but some patients remained undiagnosed for several years. The most common complications included metabolic disorders (54%) and diabetes mellitus (39%). In addition, the well‐known complications of AHP, including hypertension (22%) and malignant neoplasms of digestive organs (22%), were observed. About 10% of patients received medications that may have aggravated porphyria attacks. The estimated prevalence of AHP in Japan during the study period was 1.18 cases per 100 000 population. At time of diagnosis, many patients with AHP in Japan are already experiencing a high burden of disease‐related complications. Raising AHP awareness may aid physicians in providing an earlier diagnosis and reducing lifetime disease burden. John Wiley & Sons, Inc. 2022-10-13 /pmc/articles/PMC9830008/ /pubmed/36636592 http://dx.doi.org/10.1002/jmd2.12336 Text en © 2022 Alnylam Japan K.K and The Authors. JIMD Reports published by John Wiley & Sons Ltd on behalf of SSIEM. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Reports
Horie, Yutaka
Yasuoka, Yuka
Adachi, Tomohide
Clinical features of Japanese patients with acute hepatic porphyria
title Clinical features of Japanese patients with acute hepatic porphyria
title_full Clinical features of Japanese patients with acute hepatic porphyria
title_fullStr Clinical features of Japanese patients with acute hepatic porphyria
title_full_unstemmed Clinical features of Japanese patients with acute hepatic porphyria
title_short Clinical features of Japanese patients with acute hepatic porphyria
title_sort clinical features of japanese patients with acute hepatic porphyria
topic Research Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830008/
https://www.ncbi.nlm.nih.gov/pubmed/36636592
http://dx.doi.org/10.1002/jmd2.12336
work_keys_str_mv AT horieyutaka clinicalfeaturesofjapanesepatientswithacutehepaticporphyria
AT yasuokayuka clinicalfeaturesofjapanesepatientswithacutehepaticporphyria
AT adachitomohide clinicalfeaturesofjapanesepatientswithacutehepaticporphyria